Arbutus Biopharma Corp Accrued Professional Fees, Current
Arbutus Biopharma Corp (ABUS) had Accrued Professional Fees, Current of $735.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Payables and Accruals › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedProfessionalFeesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Professional Fees, Current $735.00K.
- 2026-03-31: Accrued Professional Fees, Current $1.57M.
- 2025-12-31: Accrued Professional Fees, Current $1.07M.
- 2025-09-30: Accrued Professional Fees, Current $443.00K.
| Period end | Accrued Professional Fees, Current |
|---|---|
| 2026-06-30 | $735.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.57M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $1.07M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $443.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $352.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.24M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.16M 10-K · filed 2026-03-23 |
| 2024-09-30 | $709.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.97M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.17M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $815.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $691.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $683.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $580.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $512.00K 10-K · filed 2024-03-05 |
| 2022-09-30 | $315.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $415.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $610.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $983.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | $582.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $443.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $690.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | $679.00K 10-K · filed 2022-03-03 |
| 2020-09-30 | $447.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $304.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $360.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $809.00K 10-K · filed 2021-03-04 |
| 2019-09-30 | $1.18M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $566.00K 10-Q · filed 2019-08-05 |
| 2019-03-31 | $491.00K 10-Q · filed 2019-05-06 |
| 2018-12-31 | $871.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | $722.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $393.00K 10-Q · filed 2018-08-03 |
| 2018-03-31 | $1.22M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $429.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $226.00K 10-Q · filed 2017-11-02 |
| 2017-06-30 | $305.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $514.00K 10-Q · filed 2017-05-04 |
| 2016-12-31 | $498.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $264.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $568.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $919.00K 10-Q · filed 2016-05-04 |
| 2015-12-31 | $640.00K 10-K · filed 2017-03-22 |
| 2015-09-30 | $336.00K 10-Q · filed 2015-11-05 |
| 2015-06-30 | $604.00K 10-Q · filed 2015-08-07 |
| 2015-03-31 | $1.75M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $1.29M 10-K · filed 2016-03-09 |
| 2014-09-30 | $525.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $147.00K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $553.00K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $247.00K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |